Dopamine replacement for Parkinson's disease (PD) have seen three major iterations of improvements since the introduction of l-3,4-dihydroxyphenylalanine (l-DOPA) pharmacotherapy: dopamine receptor agonists, ex vivo gene transfer for cell transplantation and most recently in vivo gene therapy. In this chapter, we describe the principles behind viral vector-mediated enzyme replacement in PD. We focus on the enzymes involved in the dopamine synthesis and their internal regulation, the early experimental work on gene therapy using different viral vector types and selection of transgenes, and finally discuss the recently completed early phase clinical trials in PD patients.
Sidor (från-till)221-235
TidskriftProgress in Brain Research
StatusPublished - 2010

Ämnesklassifikation (UKÄ)

  • Neurovetenskaper


Utforska forskningsämnen för ”Gene therapy for dopamine replacement.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här